MEMORANDUM

To: Committee on Audit, Risk and Compliance

From: Douglas A. Gage, Ph.D.
Vice President for Research and Innovation

Subject: Approval of Contract Terms: Advertent Biotherapeutics

RECOMMENDATION
The Trustee Committee on Audit, Risk and Compliance recommends that the Board of Trustees approve a contract between Michigan State University and Advertent Biotherapeutics, a Michigan for-profit corporation, in which MSU faculty member Dr. Erik Martinez Hackert holds a financial interest.

RESOLUTION
BE IT RESOLVED, that the Board of Trustees of Michigan State University hereby approves a service agreement with Advertent Biotherapeutics, consistent with earlier public notice and with a “Services Agreement Term Sheet” now presented to the Board for inclusion in its minutes.

BACKGROUND
In compliance with State law, public notice of the University’s intent to negotiate contracts with Advertent Biotherapeutics, a Michigan for-profit corporation, was given prior to the October 28, 2022, Board of Trustees meeting. The terms of a services agreement are now presented for Board approval.

Dr. Erik Matthias Martinez Hackert, an Associate Professor in the Department of Biochemistry and Molecular Biology, and his spouse, are co-founders, officers, have stocks in, and have stock options in Advertent Biotherapeutics. Dr. Martinez Hackert proposes to serve as the Primary Investigator on a subcontract the university received from Advertent Biotherapeutics. Dr. Martinez Hackert was not involved in the negotiations for this agreement. His spouse is the PI for the grant for Advertent Biotherapeutics. The study is currently a Phase I Small Business Innovation Research (SBIR) grant through the National Institutes of Health. Because it is in Phase I, the Conflict of Interest restrictions that normally accompany to federal grants are relaxed.

The attached “Services Agreement Term Sheet” summarizes the agreement that MSU has negotiated with Advertent Biotherapeutics.

cc: Board of Trustees, S. Stanley, M. Woo, T. Woodruff, N. Beauchamp, M. Zeig, J. Swartz, B. Quinn, L. Kriser
SERVICE AGREEMENT TERM SHEET

Party: Advertent Biotherapeutics

Project Description: MSU will be producing a drug protein from technology it has patented that Advertent will use to develop a novel therapy for muscle degeneration in Duchenne muscular dystrophy.

Term: September 2022-August 2023

Payment Terms: Advertent Biotherapeutics paying MSU, not to exceed $10,237.

Services Provided: By MSU to Advertent Biotherapeutics:
Production of purified pirin protein

By Advertent Biotherapeutics to MSU: None contemplated under this agreement.

Use of University Facilities/Personnel: Work is to be performed at MSU’s Biochemistry Building.

Organization Type: Michigan for-profit company

Personnel Interest: Dr. Erik Martinez Hackert, Associate Professor, Department of Biochemistry and Molecular Biology, and his spouse are officers of this company, own stock, and have stock options. The current value of their ownership interests is less than $5000. His spouse is the CEO, while he is the CSO. Dr. Martinez Hackert will serve as the Primary Investigator for MSU on a subaward from Advertent. His spouse is the Primary Investigator for Advertent Biotherapeutics.
MEMORANDUM

To: Committee on Audit, Risk and Compliance

From: Douglas A. Gage, Ph.D.
Vice President for Research and Innovation

Subject: Approval of Contract Terms: Scarlet Spartan Solution, LLC

RECOMMENDATION

The Trustee Committee on Audit, Risk and Compliance recommends that the Board of Trustees approve a contract between Michigan State University and Scarlet Spartan Solution, LLC, a Michigan limited liability company, in which MSU Research Associate, Dr. Justin Scott, holds a financial interest.

RESOLUTION

BE IT RESOLVED, that the Board of Trustees of Michigan State University hereby approves a service agreement with Scarlet Spartan Solution, LLC, with a “Services Agreement Term Sheet” now presented to the Board for inclusion in its minutes.

BACKGROUND

The terms of a services agreement are presented for Board approval.

MSU has previously purchased these services from Scarlet Spartan Services. Dr. Scott is in the College of Engineering. The College of Osteopathic Medicine purchased these services. Dr. Scott is not in COM and has no oversight of COM purchasing decisions.

The attached “Services Agreement Term Sheet” summarizes the agreement that MSU has negotiated with Scarlet Spartan Solutions.

cc: Board of Trustees, S. Stanley, M. Woo, T. Woodruff, N. Beauchamp, M. Zeig, J. Swartz, B. Quinn, L. Kriser
SERVICE AGREEMENT TERM SHEET

**Party:** Scarlet Spartan Solution, LLC

**Project Description:** The College of Osteopathic Medicine (COM) will be purchasing a spreadsheet that assists in analyzing student hospital placement ranking. COM will use the spreadsheet to track which students will be placed at each clinical rotation site, including the rank each student gave to the hospital in which they were placed, overall average ranking of each hospital, and the average and standard deviation of the rank each student gave to the hospital in which they were placed. The company will also provide a histogram of the rank students gave to the hospital in which they were placed.

**Term:** February 2022 – February 2023

**Payment Terms:** Not to exceed $9,000 to MSU in one-time purchase fee.

**Services Provided:**
- By MSU to Scarlet Spartan Solutions: None contemplated under this agreement
- By Scarlet Spartan Solutions to MSU: student hospital placement ranking and histogram spreadsheet.

**Use of University Facilities/Personnel:** None.

**Organization Type:** Michigan limited liability company

**Personnel Interest:** Dr. Julian Scott, a Research Associate in Mechanical Engineering, is the founder and owner of Scarlett Spartan Solution.